Announced
ANP Technologies terminated the merger with Sorrento Therapeutics.
Synopsis
ANP Technologies, an emerging nanobiotechnology company, terminated the merger with Sorrento Therapeutics, an antibody-centric, clinical stage biopharmaceutical company. The effect of this termination now allows ANP to freely explore other business opportunities with parties interested in ANP’s diagnostic and platform drug delivery technologies.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.